• Cost of Sovaldi in different countries, and how these lower costs are accounted for within Gilead's financials The senators are trying to understand if Sovaldi is worth the expense and if it ...

Gilead has signed a deal with seven India-based generics firms which will see them manufacture hepatitis C drug Sovaldi for no fewer than 91 developing countries. The deal is an extremely bold ...

In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...

In 2013, Gilead Sciences Inc. (NASDAQ: GILD) received FDA approval for its hepatitis C virus (HCV) medication, Sovaldi. This miracle cure had a 90% to 96% success rate for curing HCV. A once-a-day ...

Gilead Sciences, Inc ... Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence ...

For all its benefits, Gilead’s revolutionary medicine, Sovaldi, drew criticism for its price tag: $84,000—or about $1,000 a pill—in the U.S. Gilead, which also brings in around $9 billion ...

Tyler Van Buren, an analyst from TD Cowen, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target ...

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn from Morgan Stanley upgraded the rating on the stock ...